Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

8.900 +0.050 (+0.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
Recap: Arcturus Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
Earnings Preview: Arcturus Therapeutics ↗
 
Via Benzinga
News headline image
Evaluating NASDAQ:ARCT for Growth Investment Opportunities. ↗
High growth, ROE and beating expectations for NASDAQ:ARCT: growth investors may appreciate this. 
Via Chartmill
News headline image
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Cathie Wood-Led Ark Invest Dumps $4.3M Worth Of Nvidia Shares Amid Rebound — Swoops Into Buy Stock Of This Netflix Rival ↗
 
Via Benzinga
News headline image
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Cathie Wood-Led Ark Invest Sells $1.5M Worth Of Robinhood Shares Amid Muted Bitcoin Market — Also Dumps Zoom Stock Worth $3.3M ↗
Ark Invest, led by Cathie Wood, made significant trades on Wednesday involving Robinhood Markets Inc (NASDAQ:HOOD) and Zoom Video Communications Inc (NASDAQ:ZM). 
Via Benzinga
News headline image
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness ↗
On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a... 
Via Benzinga
News headline image
Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst ↗
Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, showing FEV1 improvements and safety . 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic ↗
Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung function. 
Via Benzinga
News headline image
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
From Achilles Therapeutics PLC
Via GlobeNewswire
News headline image
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
From Arcturus Therapeutics
Via Business Wire
News headline image
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential' ↗
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists. 
Via Benzinga
News headline image
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Misses Revenue for Q4 2023 ↗
ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 7, 2024 ↗
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.